Objective: To describe estimated blood loss (EBL) with surgical abortion ≤14 weeks' gestation in anticoagulated patients. Study design: We invited 170 clinicians involved in a professional listserv to report cases when they performed a surgical abortion on a patient ≤14 weeks' gestation taking an anticoagulant. Clinicians reported EBL and bleeding-related complications (need for a blood transfusion, additional surgical procedures to treat bleeding). We contacted clinicians 30 days postprocedure to capture postoperative complications. Results: Clinicians reported 52 cases between February 2011 and October 2013. Thirty percent of patients (16/52) stopped the anticoagulant with adequate time for the effects to abate prior to surgery (6 h for heparin, 24 h for low-molecular-weight heparin, International Normalized Ratio ≤1.7 the day prior to surgery for warfarin), while 69% (36/52) continued the anticoagulant either at therapeutic (25/36) or subtherapeutic (16/36) doses. Seventy-eight percent (28/36) of patients who continued the anticoagulant had an EBL of 50 mL or less compared to 88% (14/16) of those who stopped the anticoagulant with adequate time for its effects to abate (p=.73). Bleeding-related complications occurred in four anticoagulated patients and none of the patients who discontinued anticoagulant therapy. Conclusion: Continuation of anticoagulation for planned surgical abortion under 84 days does not appear to be associated with heavy bleeding.
|Original language||English (US)|
|State||Accepted/In press - Jan 28 2016|
- Low molecular weight heparin
ASJC Scopus subject areas
- Reproductive Medicine
- Obstetrics and Gynecology